Back to Search Start Over

Psychiatric illness and regression in individuals with Phelan-McDermid syndrome

Authors :
Alexander Kolevzon
Audrey Thurm
M. Pilar Trelles
Catalina Betancur
Teresa M. Kohlenberg
Brittany McLarney
Betancur, Catalina
Department of Psychiatry [Worcester, MA, USA]
University of Massachusetts Medical School [Worcester] (UMASS)
University of Massachusetts System (UMASS)-University of Massachusetts System (UMASS)
Seaver Autism Center for Research and Treatment [New York, NY, USA]
Icahn School of Medicine at Mount Sinai [New York] (MSSM)
Department of Psychiatry [New York, NY, USA]
Phelan-McDermid Syndrome Foundation [Osprey, FL, USA]
Neuroscience Paris Seine (NPS)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut de Biologie Paris Seine (IBPS)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)
Neurodevelopmental and Behavioral Phenotyping Service [Bethesda, MD, USA] (Intramural Research Program)
National Institute of Environmental Health Sciences [Durham] (NIEHS-NIH)
National Institutes of Health [Bethesda] (NIH)-National Institutes of Health [Bethesda] (NIH)
MPT receives research support from the National Institute of Health National Research Service Award Institutional Training Program (T32) and the Beatrice and Samuel A. Seaver Foundation. AT receives support from the Intramural Research Program of the National Institute of Mental Health (ZICMH002961). AK receives support from the National Institute of Neurological Disorders and Stroke (R01NS105845-01 and U54 NS092090-01) and from the Beatrice and Samuel A. Seaver Foundation.
Neurosciences Paris Seine (NPS)
Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Biologie Paris Seine (IBPS)
Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)
Source :
Journal of Neurodevelopmental Disorders, Vol 12, Iss 1, Pp 1-17 (2020), Journal of Neurodevelopmental Disorders, Journal of Neurodevelopmental Disorders, 2020, 12 (1), pp.7. ⟨10.1186/s11689-020-9309-6⟩, Journal of Neurodevelopmental Disorders, BioMed Central, 2020, 12 (1), pp.7. ⟨10.1186/s11689-020-9309-6⟩
Publication Year :
2020
Publisher :
BMC, 2020.

Abstract

Background Phelan-McDermid syndrome (PMS) is a genetic condition characterized by intellectual disability, speech and language deficits, hypotonia, autism spectrum disorder, and epilepsy. PMS is caused by 22q13.33 deletions or mutations affecting SHANK3, which codes for a critical scaffolding protein in excitatory synapses. SHANK3 variants are also known to be associated with an increased risk for regression, as well as for psychiatric disorders, including bipolar disorder and catatonia. This study aimed to further describe these phenomena in PMS and to explore any relationship between psychiatric illness and regression after early childhood. Methods Thirty-eight people with PMS were recruited to this study through the Phelan-McDermid Syndrome Foundation based on caregiver report of distinct development of psychiatric symptoms. Caregivers completed a clinician-administered semi-structured interview focused on eliciting psychiatric symptomatology. Data from the PMS International Registry were used to confirm genetic diagnoses of participants and to provide a larger sample for comparison. Results The mean age of the 38 participants was 24.7 years (range = 13 to 50; SD = 10.06). Females (31 of 38 cases; 82%) and sequence variants (15 of 38 cases; 39%) were over-represented in this sample, compared to base rates in the PMS International Registry. Onset of psychiatric symptoms occurred at a mean age of 15.4 years (range = 7 to 32), with presentations marked by prominent disturbances of mood. Enduring substantial loss of functional skills after onset of psychiatric changes was seen in 25 cases (66%). Symptomst indicative of catatonia occurred in 20 cases (53%). Triggers included infections, changes in hormonal status, and stressful life events. Conclusions This study confirms that individuals with PMS are at risk of developing severe neuropsychiatric illness in adolescence or early adulthood, including bipolar disorder, catatonia, and lasting regression of skills. These findings should increase the awareness of these phenotypes and lead to earlier diagnosis and the implementation of appropriate interventions. Our findings also highlight the importance of genetic testing in the work-up of individuals with intellectual disability and acute psychiatric illness or regression. Future research is needed to clarify the prevalence and nature of psychiatric disorders and regression among larger unbiased samples of individuals with PMS.

Details

Language :
English
ISSN :
18661955 and 18661947
Volume :
12
Issue :
1
Database :
OpenAIRE
Journal :
Journal of Neurodevelopmental Disorders
Accession number :
edsair.doi.dedup.....9aeabe23388e6ee5f7f6c582d5e76c6a